#ASH2025—far
LightNews LightNews
d-and-d-world.bsky.social
Gallop’s LYT-200 shows 13.2-month median survival in late-line AML at #ASH2025—far exceeding historic benchmarks. The anti-galectin-9 antibody combines strong efficacy with a clean safety profile.

#News #Leukemia #Oncology #Biotech #ClinicalTrials #AML
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
druganddeviceworld.com
January 6, 2026 at 2:37 PM
phalguniddw.bsky.social
Gallop’s LYT-200 shows 13.2-month median survival in late-line AML at #ASH2025—far exceeding historic benchmarks. The anti-galectin-9 antibody combines strong efficacy with a clean safety profile.

#News #Leukemia #Oncology #Biotech #ClinicalTrials #AML
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
druganddeviceworld.com
January 6, 2026 at 2:37 PM
hcplivenews.bsky.social
New from #ASH2025: Platelet transfusion effectively reduces the number of thrombotic events in patients with ITP, but significantly increases the risk of mortality. Manas Pustake, MD, discusses why this procedure should be used far more conservatively.

Watch now:
Platelet Transfusion Raises Mortality Risk in Consumptive Thrombocytopenia, with Manas Pustake, MD | HCPLive
Pustake highlights the reticence with which clinicians should approach providing platelet transfusion to patients.
www.hcplive.com
December 17, 2025 at 3:00 PM